HOME >> MEDICINE >> NEWS
Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit

Corautus Genetics Inc. (NASDAQ:VEGF) announced today the publication of the two year follow-up results of the Corautus' earlier Phase I study of VEGF-2 in patients with severe angina. In this trial, Vascular Endothelial Growth Factor-2 (VEGF-2), in the form of "naked" plasmid DNA (a non-viral delivery vector) was delivered in defined doses by direct injection into the heart muscle. Results of the follow-up study, as reported by the investigators in the current issue of the Journal of Interventional Cardiology (JOIC) (Vol. 18, No. 1, pp. 27 31, 2005), demonstrate prolonged clinical benefit as measured by improvement of patients' angina two years following treatment (p < 0.05) with no reported complications directly related to the gene therapy procedure. The Journal article and full publication are available on line at www.blackwellpublishing.com/joic .

Corautus' technology is currently being tested in a randomized, double-blinded, dose-ranging and placebo-controlled Phase IIb clinical trial known as GENASIS ("Genetic Angiogenic Stimulation Investigational Study"), which will enroll 404 patients with Class III or IV angina that are not suitable candidates for traditional revascularization procedures. The GENASIS trial will be conducted in approximately 25 cardiac medical centers throughout the United States. In the GENASIS trial, defined doses of VEGF-2 in the form of "naked" plasmid DNA are delivered to diseased heart muscle tissue via the Boston Scientific Corporation (NYSE: BSX) Stiletto(TM) endocardial direct injection catheter system. The injection procedure is performed by a cardiologist in a standard cardiac laboratory. Corautus expects to complete patient enrollment of the Phase IIb trial around the end of 2005.

Dr. Douglas W. Losordo, the national Principal Investigator for the GENASIS trial and Chief of Cardiovascular Research at Caritas St. Elizabeth's Medical Center in Bosto
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
8-Mar-2005


Page: 1 2 3 4 5

Related medicine news :

1. Many children are undervaccinated or have delayed vaccinations in their first 2 years of life
2. 14-year study finds that quitting smoking adds years to life
3. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
4. Cumulative trauma in adulthood can worsen health in later years
5. Malnutrition in early years leads to low IQ and later antisocial behavior, USC study finds
6. Vioxx should have been withdrawn 4 years ago
7. Cancer burden seen even many years after diagnosis
8. Scientists meet to review Envisat results after two and a half years of operations
9. Study finds lung transplants increase survival of cystic fibrosis patients by more than four years
10. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years
11. Full recovery after cell transplantation for treating leukemia or lymphoma can take 3-5 years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
Cached News: